|
Pain scores (pain was scored on a visual analog scale where 0 = no pain and 100 = the highest possible pain level). |
||||||||
| Baseline |
SAMe |
Celecoxib |
||||||
|
|
||||||||
| Variable |
N+ |
Mean |
(SD) |
Mean |
(SD) |
Mean |
(SD) |
Stdif |
|
|
||||||||
| Pain Level Today |
||||||||
|
|
||||||||
| Month 1 |
52 |
45.3 |
(23.8) |
33.8* |
(24.0) |
24.6* |
(23.9) |
-0.33* |
| Month 2 |
52 |
46.1 |
(24.2) |
24.0* |
(19.5) |
24.4* |
(23.6) |
0.01 |
|
|
||||||||
| Pain Level over the Past Month |
||||||||
|
|
||||||||
| Month 1 |
52 |
56.7 |
(22.5) |
44.1* |
(22.4) |
32.5* |
(24.0) |
-0.42** |
| Month 2 |
52 |
57.0 |
(23.4) |
34.7* |
(22.7) |
33.1* |
(22.8) |
-0.05 |
|
Stdif: Standardized difference scores – positive numbers indicate a better response with SAMe. +Sample size is less than 57 due to missing data in either Phase 1 or Phase 2. *Difference between baseline and treatment is statistically significant (p < 0.05). ** Difference between SAMe and Celecoxib is statistically significant (p < 0.05). | ||||||||
Najm et al. BMC Musculoskeletal Disorders 2004 5:6 doi:10.1186/1471-2474-5-6 |
||||||||